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Hearing Loss after Discontinuing Secondary
Prophylaxis for Cryptococcal Meningitis:
Relapse or Immune Reconstitution?
N. Khanna, R. Nüesch, C. Buitrago-Tellez, M. Battegay, H.H. Hirsch
Abstract
Relapse and immune reconstitution syndrome are difficult to 
distinguish in HIV-infected patients treated with antiretro-
viral therapy (ART). We report on a 26-year-old HIV-infected 
male (CDC C3) with hearing loss on the right side 2 months 
after discontinuing secondary prophylaxis for cryptococcal 
meningitis. CD4 cell counts had increased from 32/µl to 
stable counts > 200/µl for the preceding 6 months on ART 
but HIV replication was not fully suppressed (7,000 copies/
ml). Magnetic resonance imaging identified lesions at the 
origin of the right cranial nerve VIII.  Lumbar puncture 
revealed monocytic pleocytosis, slightly increased protein, 
but normal glucose and lactate levels, negative microbio-
logical studies. Fluconazole was restarted and a new ART 
regimen was started in order to fully suppress HIV repli-
cation. Clinical and radiological signs were reversible during 
follow-up, and secondary prophylaxis was stopped after 
6 months without adverse events. We review 26 published 
cases of cryptococcal infections with immune reconstitution 
syndrome and highlight the distinguishing features. 
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Introduction
The discontinuation of secondary prophylaxis for cryp-
tococcal meningitis is considered safe in HIV-infected 
patients on highly active antiretroviral therapy (ART) with 
stable CD4 cell counts > 100 cells/µl. This is supported by 
data from prospective studies [1], cohort studies [2] and 
summarized in current guidelines [3]. However, despite 
clinical success and improved CD4 counts, paradoxical 
worsening of the clinical condition has been observed in 
some cases. The differential diagnosis includes relapse or 
immune reconstitution syndrome, which are difficult to 
distinguish from one another [4, 5].
Case Report
A 26-year-old male from Thailand presented with headache 
and fever to our outpatient department. Cryptococcal menin-
gitis and pneumonia was diagnosed as well as HIV-1 infection 
CDC C3 (CD4 cell counts of 32/µl; HIV viral load of 89,000 cop-
ies/ml [4.9 log 10]). Cryptococcus neoformans antigen was posi-
tive in blood (1:1,024). Computer scan of the neurocranium was 
unremarkable. In the cerebrospinal fluid (CSF), pleocytosis with 
507/µl polymorphs, elevated lactate (3.4 mmol/l), elevated pro-
tein (747 mg/l) and C. neoformans was identified by culture. The 
patient was treated with amphotericin-B and flucytosine. The 
clinical condition improved, and antigen titers decreased. Second-
ary prophylaxis with fluconazole 400 mg daily was administered 
as well as trimethoprim/sulfamethoxazole (TMP/SMX) three 
times weekly as primary prophylaxis for Pneumocystis carinii 
(jiroveci). ART was initiated consisting of stavudine, lamivudine 
and nelfinavir (Figure 1A). The HIV-RNA viral load decreased 
by 2 log 10 and CD4 cell counts increased to 234/µl over the fol-
lowing 6 months. However, HIV replication was sub-optimally 
suppressed with viral loads around 2,000 copies/ml. ART was 
switched to didanosine, lamivudine and nevirapine but without 
significant improvement. After 9 months of stable CD4 cell counts 
above 200/µl, secondary prophylaxis with fluconazole was stopped 
(Figure 1A). Two months later, the patient presented with sud-
den hearing loss on the right side. The clinical examination was 
otherwise unremarkable and there was no evidence of vertigo. The 
audiogramm revealed right-sided central hearing loss at 1,000 Hz. 
Magnetic resonance imaging of the brain showed multiple small 
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contrast enhancing lesions with 
edema in the left and right cortex 
and a major lesion in the right cer-
ebellum near the root of the eighth 
cranial nerve which also emerged 
in T2 weigted imaging (Figure 1B). 
In the CSF, monocytic pleocytosis 
(16/µl), low lactate (1.3 mmol/l), 
low glucose (2.9 mmol/l) and nor-
mal protein levels (480 mg/l) were 
detected. Bacterial and fungal cul-
ture remained negative. Also, nega-
tive results were obtained for cryp-
tococcal antigen, cysticercosis anti-
bodies, and PCR studies specific for 
M. tuberculosis, cytomegalovirus, 
polyomavirus JC, Toxoplasma gon-
dii, and Epstein-Barr virus. The dif-
ferential diagnosis included relapsing 
cryptococcal infection or immune 
reconstitution syndrome. Flucon-
azole was restarted (400 mg/day). 
HIV resistance testing was performed 
and ART was changed accordingly to 
zidovudine, didanosine and lopinavir/
ritonavir. The HIV-RNA viral load 
dropped under the detection limit 
(Figure 1A). Six weeks later, hear-
ing loss was unchanged, but painful 
cervical lymphadenopathy devel-
oped. Biopsy of a cervical lymph 
node showed granulomas with 
cryptococci (Figure 1D). Cultures 
from lymph tissue remained nega-
tive, but Cryptococcus antigen was 
detectable in lymph node extracts. 
After 3 months, hearing improved 
and decreasing lesion intensity was 
noted in the MRI (Figure 1C). After 
12 months, the CD4 cell counts mea-
sured 392/µl and the HIV-RNA viral 
load remained < 50 copies/ml. Fluco-
nazole was discontinued and no signs 
of relapse occurred during a follow-
up of 30 months. Audiogram con-
firmed a near complete recovery.
Discussion
Central neurological symp-
toms (central hearing loss) and 
extensive MRI lesions were 
unexpected in view of adequate 
antimicrobial therapy and stable 
CD4 cell counts above 200/µL for 
more than 6 months. Although 
we could not diagnose ongoing 
cryptococcal disease, relapse 
had to be considered. On the 
other hand, CSF pleocytosis and 
contrast enhancement in MRI 
rendered immune reconstitution 
Figure 1. A) Time course of HIV surrogate markers (CD4 cell counts, circles, left axis; HIV viral load in 
log 10, triangels, right axis), drug treatment in boxes (stavudine, d4T; lamivudine, 3TC; zidovudine, 
AZT; nelfinavir, NFV; didanosine, DDI; nevirapine, NVP; lopinavir/ritonavir, LPV/r) and MRI in boxes. 
B) T2-weighted MRI of the head at diagnosis showing hyperintense lesion with edema in the right 
cerebellum and in the brain stem near the meatus acusticus internus. C) T2-weighted MRI of the 
head 9 months later showing dissolved lesion and edema in the right cerebellum and in the brain 
stem near the meatus acusticus internus. D) Lymph node histology showing granuloma with 
Cryptococcus neoformans (culture negative, antigen positive).
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syndrome another likely diagnosis. The subsequent onset 
of granulomatous lymphadenitis with non-viable C. neofor-
mans also supported this hypothesis, but the long time of 
onset of more than 6 months after starting ART is unusual. 
In the literature, variable durations of 5 days to 34 months 
have been reported with increases in CD4 cell counts 
ranging from 3 to 637/µl (Table 1 [5, 7–19]). In some cases, 
IRS may in fact unmask hitherto undiagnosed cryptococ-
cosis [5]. Table 1 lists 26 published cases with cryptococcal 
infections that developed an IRS after initiation of highly 
active antiretroviral therapy [5, 7–19]. At the time when 
IRS developed the CD4 count increased in 21 patients > 
twofold and viral load decreased > 2log 10 copies/ml. Simi-
lar to our case, cryptococcal relapse could not be excluded 
in 20 patients who were therefore treated with antifun-
gal therapy (Amphothericin B or high dose fluconazole) 
and secondary prophylaxis. In five patients, inflammatory 
treatment with steroids or non steroidal anti-inflammatory 
drugs was administered. All patients recovered from IRS. 
No significant correlation between initial signs and symp-
toms and the subsequent manifestation of IRS are appar-
ent. 
IRS occurs in 10–30% of patients treated with ART 
and is associated a variety of microbial and non-microbial 
antigens. Often, initial CD4 cell counts are very low and 
briskly increase after starting ART [4]. Mycobacterial and 
cryptococcal antigens are frequently implicated in IRS. 
Indeed, a recent study found C. neoformans-related IRS 
in 30% of HIV-patients [6]. Compared to patients without 
IRS, patients with C. neoformans-related IRS had a lower 
HIV viral load, higher CD4 cell count, a higher CSF-open-
ing pressure, higher mononuclear pleocytosis and lower 
cryptococcal antigen titer in the CSF. However, clinical 
signs and symptoms were not specific. Antifungal treat-
ment was administered in all cases which emphasizes the 
clinical dilemma of suspected relapse versus IRS. Of note, 
neither relapse nor immune reconstitution was reported 
in a recent prospective study [1]. All patients in this study 
had optimally suppressed HIV viral loads of < 50 copies/
ml. One may speculate whether sub-optimally suppressed 
HIV replication in our patient may have preferentially 
infected and hence, deleted the Cryptococcus-specific 
CD4 cells which were activated by abundant antigen. The 
hypothesis may account for a true relapse despite CD4 cell 
counts > 200/µl and may explain the initial signs and symp-
toms in our patient. Possibly, discontinuation of secondary 
prophylaxis may bear a higher risk in sub-optimally sup-
pressed HIV-patients. 
References
1.  Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, 
Tansuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A: 
Discontinuation of secondary prophylaxis for cryptococcal 
meningitis in human immunodeficiency virus-infected patients 
treated with highly active antiretroviral therapy: a prospec-
tive, multicenter, randomized study. Clin Infect Dis 2003; 36: 
1329–1331.
2.  Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, 
Wit FW, Ledergerber B, Lundgren JD, Furrer H: European HIV 
Cohorts. Safe interruption of maintenance therapy against 
previous infection with four common HIV-associated 
opportunistic pathogens during potent antiretroviral therapy. 
Ann Intern Med 2002; 137: 239–250.
3.  Kaplan JE, Masur H, Holmes KK: Guidelines for preventing 
opportunistic infections among HIV-infected persons–2002. 
Recommendations of the U.S. Public Health Service and the 
Infectious Diseases Society of America 639. MMWR Recomm 
Rep 2002; 51: 1–52.
4.  Hirsch HH, Kaufmann G, Sendi P, Battegay M: Immune 
reconstitution in HIV-infected patients. Clin Infect Dis 2004; 
38: 1159–1166.
5.  Woods ML, MacGinley R, Eisen DP, Allworth AM: HIV combina-
tion therapy: partial immune restitution unmasking latent 
cryptococcal infection. AIDS 1998; 12: 1491–1494.
6.  Shelburne SA 3rd, Darcourt J, White AC Jr, Greenberg SB, 
Hamill RJ, Atmar RL, Visnegarwala F: The role of immune 
reconstitution inflammatory syndrome in AIDS-related 
Cryptococcus neoformans disease in the era of highly active 
antiretroviral therapy. Clin Infect Dis 2005; 40: 1049–1052.
7. Jenny-Avital ER, Abadi M: Immune reconstitution cryptococcosis 
after initiation of successful highly active antiretroviral therapy. 
Clin Infect Dis 2002; 35: e128–e133.
8. Trevenzoli M, Cattelan AM, Rea F, Sasset L, Semisa M, Lanzafame 
M, Meneghetti F, Cadrobbi P: Mediastinitis due to cryptococcal 
infection: a new clinical entity in the HAART era. J Infect 2002; 
45: 173–179.
9. Cattelan AM, Trevenzoli M, Sasset L, Lanzafame M, Marchioro 
U, Meneghetti F: Multiple cerebral cryptococcomas associated 
with immune reconstitution in HIV-1 infection. AIDS 2004; 18: 
349–351.
10. Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW: 
Relapsing meningitis caused by persistent cryptococcal 
antigens and immune reconstitution after the initiation of 
highly active antiretroviral therapy. AIDS 2004; 18: 1223–1224.
11. Rambeloarisoa J, Batisse D, Thiebaut JB, Mikol J, Mrejen S, 
Karmochine M, Kazatchkine MD, Weiss L, Piketty C: 
Intramedullary abscess resulting from disseminated 
cryptococcosis despite immune restoration in a patient 
with AIDS. J Infect 2002; 44: 185–188.
12. King MD, Perlino CA, Cinnamon J, Jernigan JA: Paradoxical 
recurrent meningitis following therapy of cryptococcal 
meningitis: an immune reconstitution syndrome after 
initiation of highly active antiretroviral therapy. Int J STD 
AIDS 2002; 13: 724–726.
13. Blanche P, Gombert B, Ginsburg C, Passeron A, Stubei I, 
Rigolet A, Salmon D, Sicard D: HIV combination therapy: 
immune restitution causing cryptococcal lymphadenopathy 
dramatically improved by anti-inflammatory therapy. Scand J 
Infect Dis 1998; 30: 615-616.
14. Legendre U, Battegay M, Nuttli I, Dalquen P, Nuesch R: Simul-
taneous occurence of 2 HIV – related immunereconstitution 
diseases after initiation of highly active antiretroviral therapy. 
Scand J Infect Dis 2001; 33: 388–389.
15. Breton G, Seilhean D, Cherin P, Herson S, Benveniste O: Paradoxi-
cal intracranial cryptococcoma in a human immunodeficiency 
virus-infected man being treated with combination antiretrovi-
ral therapy. Am J Med 2002; 113: 155–157.
N. Khanna et al. Hearing Loss after Cryptococcal Meningitis
168 Infection 34 · 2006 · No. 3 © URBAN & VOGEL
16. Cinti SK, Armstrong WS, Kauffman CA: Case report. Recurrence 
of increased intracranial pressure with antiretroviral therapy in 
an AIDS patient with cryptococcal meningitis. Mycoses 2001; 44: 
497–501.
17. Lanzafame M, Trevenzoli M, Carretta G, Lazzarini L, Vento S, Con-
cia E: Mediastinal lymphadenitis due to cryptococcal infection 
in HIV-positive patients on highly active antiretroviral therapy. 
Chest 1999; 116: 848–849.
18. Manfredi R, Pieri F, Pileri SA, Chiodo F: The changing face of 
AIDS-related opportunism: cryptococcosis in the highly active 
antiretroviral therapy (HAART) era. Case reports and literature 
review. Mycopathologia 1999; 148: 73–78.
19. Skiest DJ, Hester LJ, Hardy RD: Cryptococcal immune reconstitu-
tion inflammatory syndrome: report of four cases in three 
patients and review of the literature. J Infect 2005; 51: 
e289–e297.
